These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 12497201

  • 1. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
    Matheson SL, McNamee JP, Jean-Claude BJ.
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
    [Abstract] [Full Text] [Related]

  • 2. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
    Matheson SL, McNamee JP, Wang T, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ.
    J Pharmacol Exp Ther; 2004 Dec; 311(3):1163-70. PubMed ID: 15358812
    [Abstract] [Full Text] [Related]

  • 3. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy.
    Matheson SL, McNamee J, Jean-Claude BJ.
    J Pharmacol Exp Ther; 2001 Mar; 296(3):832-40. PubMed ID: 11181914
    [Abstract] [Full Text] [Related]

  • 4. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
    Brahimi F, Matheson SL, Dudouit F, McNamee JP, Tari AM, Jean-Claude BJ.
    J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
    [Abstract] [Full Text] [Related]

  • 5. The combi-targetinG concept: intracellular fragmentation of the binary epidermal growth factor (EGFR)/DNA targeting "combi-triazene" SMA41.
    Matheson SL, Brahimi F, Jean-Claude BJ.
    Biochem Pharmacol; 2004 Mar 15; 67(6):1131-8. PubMed ID: 15006549
    [Abstract] [Full Text] [Related]

  • 6. Mechanism of action of a novel "combi-triazene" engineered to possess a polar functional group on the alkylating moiety: evidence for enhancement of potency.
    Brahimi F, Rachid Z, McNamee JP, Alaoui-Jamali MA, Tari AM, Jean-Claude BJ.
    Biochem Pharmacol; 2005 Aug 15; 70(4):511-9. PubMed ID: 15982640
    [Abstract] [Full Text] [Related]

  • 7. The combi-targeting concept: chemical dissection of the dual targeting properties of a series of "combi-triazenes".
    Rachid Z, Brahimi F, Katsoulas A, Teoh N, Jean-Claude BJ.
    J Med Chem; 2003 Sep 25; 46(20):4313-21. PubMed ID: 13678409
    [Abstract] [Full Text] [Related]

  • 8. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.
    Qiu Q, Dudouit F, Matheson SL, Brahimi F, Banerjee R, McNamee JP, Jean-Claude BJ.
    Cancer Chemother Pharmacol; 2003 Jan 25; 51(1):1-10. PubMed ID: 12497200
    [Abstract] [Full Text] [Related]

  • 9. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
    Qiu Q, Domarkas J, Banerjee R, Katsoulas A, McNamee JP, Jean-Claude BJ.
    Anticancer Drugs; 2007 Feb 25; 18(2):171-7. PubMed ID: 17159603
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of platelet-derived growth factor-mediated signal transduction and tumor growth by N-[4-(trifluoromethyl)-phenyl]5-methylisoxazole-4-carboxamide.
    Shawver LK, Schwartz DP, Mann E, Chen H, Tsai J, Chu L, Taylorson L, Longhi M, Meredith S, Germain L, Jacobs JS, Tang C, Ullrich A, Berens ME, Hersh E, McMahon G, Hirth KP, Powell TJ.
    Clin Cancer Res; 1997 Jul 25; 3(7):1167-77. PubMed ID: 9815796
    [Abstract] [Full Text] [Related]

  • 11. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 12. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.
    Qiu Q, Domarkas J, Banerjee R, Merayo N, Brahimi F, McNamee JP, Gibbs BF, Jean-Claude BJ.
    Clin Cancer Res; 2007 Jan 01; 13(1):331-40. PubMed ID: 17200372
    [Abstract] [Full Text] [Related]

  • 13. Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression.
    Ahmad N, Gali H, Javed S, Agarwal R.
    Biochem Biophys Res Commun; 1998 Jun 18; 247(2):294-301. PubMed ID: 9642119
    [Abstract] [Full Text] [Related]

  • 14. Loss of cytotoxic effect of epidermal growth factor (EGF) on EGF receptor overexpressing cells is associated with attenuation of EGF receptor tyrosine kinase activity.
    Gardner DP, Shimizu N.
    J Cell Physiol; 1994 Feb 18; 158(2):245-55. PubMed ID: 8106561
    [Abstract] [Full Text] [Related]

  • 15. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
    Liu Y, Poon RT, Shao W, Sun X, Chen H, Kok TW, Fan ST.
    Cancer Lett; 2007 Apr 08; 248(1):32-40. PubMed ID: 16837130
    [Abstract] [Full Text] [Related]

  • 16. Expression of functional epidermal growth factor receptors in a human hematopoietic cell line.
    Oval J, Hershberg R, Gansbacher B, Gilboa E, Schlessinger J, Taetle R.
    Cancer Res; 1991 Jan 01; 51(1):150-6. PubMed ID: 1703031
    [Abstract] [Full Text] [Related]

  • 17. The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR).
    Domarkas J, Dudouit F, Williams C, Qiyu Q, Banerjee R, Brahimi F, Jean-Claude BJ.
    J Med Chem; 2006 Jun 15; 49(12):3544-52. PubMed ID: 16759097
    [Abstract] [Full Text] [Related]

  • 18. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor.
    Rewcastle GW, Palmer BD, Bridges AJ, Showalter HD, Sun L, Nelson J, McMichael A, Kraker AJ, Fry DW, Denny WA.
    J Med Chem; 1996 Feb 16; 39(4):918-28. PubMed ID: 8632415
    [Abstract] [Full Text] [Related]

  • 19. Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer.
    Kalli KR, Bradley SV, Fuchshuber S, Conover CA.
    Gynecol Oncol; 2004 Sep 16; 94(3):705-12. PubMed ID: 15350362
    [Abstract] [Full Text] [Related]

  • 20. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
    Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R.
    Clin Cancer Res; 2007 Jul 15; 13(14):4291-9. PubMed ID: 17634559
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.